Filing Details
- Accession Number:
- 0001140361-12-052553
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-12-21 19:34:01
- Reporting Period:
- 2012-12-19
- Filing Date:
- 2012-12-21
- Accepted Time:
- 2012-12-21 19:34:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
69499 | Mylan Inc. | MYL | Pharmaceutical Preparations (2834) | 251211621 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1116509 | B C Todd | 1500 Corporate Drive Canonsburg PA 15317 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2012-12-19 | 266,749 | $27.78 | 0 | No | 4 | S | Indirect | By CSJR Partners, LP |
Common Stock | Disposition | 2012-12-19 | 29,456 | $28.01 | 37,500 | No | 4 | S | Indirect | By C.B. Todd Revocable Trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By CSJR Partners, LP |
No | 4 | S | Indirect | By C.B. Todd Revocable Trust |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 18,181 | Direct | |
Common Stock | 1,686 | Indirect | By Wife |
Common Stock | 168,747 | Indirect | By Mary Lou Todd Trusts |
Footnotes
- This sale was executed pursuant to a 10b5-1 trading plan dated December 12, 2012.
- Represents the weighted price of the reporting person's disposition of 266,749 shares in transactions ranging from $27.51 to $28.35.
- Represents the weighted price of the reporting person's disposition of 29,546 shares in transactions ranging from $27.75 to $28.34.
- The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2 to this Form 4.